NEK2 and Miyoshi myopathy: Compared with healthy donors (HD), NEK2 amplification (defined as ≥20% of CD138+ cells with three or more FISH signals) was detected in 23.5% (5/17), 75% (3/4), and 87.5% (7/8) of newly diagnosed MM patients (AD), relapsed diagnosed MM patients (RD) and MM cell lines, respectively (Figure 1D and Table S1, Supporting Information), suggesting a link between NEK2 amplification and poor prognosis in MM.